The following brief summaries on new drugs and treatment strategies include links to the ICAAC online abstracts and/or links to slidesets or articles posted at natap.org.
The top-line results from the randomised, double-blinded, placebo-controlled, non-inferiority, Phase 3 SPRING study were released in July just prior to the IAS conference.
At week 48, the dolutegravir arm showed superiority with 88% vs 81% of patients suppresed to <50 copies/mL (difference +7.4%; 95%CI: +2.5, +12.3; p=0.003).
This result was driven by fewer discontinuations due to toxicity in the dolutegravir arm (2% vs 10%). Virological failure occured in 4% of patients in each group.
Ref: Walmsley S et al. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results -- SINGLE (ING114467). 52nd ICAAC, 9-12 September 2012, San Francisco. Abstract H-556b.
Results from two small PK studies in patients on stable opiate substitution therapy (n=12 methadone; n=18 buprenorphine) reported no indications of an interaction between elvitegravir/cobicistat and methadone and only modestly increased buprenorphine levels that did not require dose modification.
Ref: Bruce RD et al. Pharmacokinetics of cobicistat-boosted elvitegravir administered in combination with methadone or buprenorphine/naloxone. 52nd ICAAC, 9-12 September 2012, San Francisco. Abstract A-1250.
The first in vivo virological data were presented for a new long-acting formulation of the fusion inhibitor T-20. This compound is in development with the Chinese company Chongquing Biotechnologies.
The limited information from the abstract reported results from a dose-finding study in Chinese HIV positive patients who received single IV injections daily for three days, followed by once-weekly injections for a further two weeks.
Mean maximum declines of 0.68 and 1.05 log copies/mL were reported with 160 mg and 320 mg doses respectively. In a single-dose study, viral reduction was maintained for 6-10 days, with albuvirtide showing a plasma half-life of 10-13 days.
Ref: Wu H et al. Albuvirtide, the first long-acting HIV fusion inhibitor, suppressed viral replication in HIV-infected adults. 52nd ICAAC, 9-12 September 2012, San Francisco. Abstract H554.
Although results of once-daily raltegravir studies did not support a label change or further research into this dosing option, a Canadian study reported very high rates of success in a cohort of 121 HIV positive treatment experienced injecting drug users (n=103 male) that also included comprehensive adherence support. DOT ws used by 81% of patients.
Over a median follow-up of 12 (6-18) months, 80% of the cohort achieved or maintained virologic suppression to <50 copies/mL (appromiately half the group switched with undetectable viral load at baseline.
Importantly, CD4 counts increased by a median 80 cells/mm3 from a median of 425 cells/mm3 (range 20-1600) at baseline. Adherence exceeded 90%. Virologic rebound to >400 copies/mL occurred in 10% of patients but resuppression was achieved in all cases over the subsequent three months. There were no cases of emergent raltegravir resistance.
Ref: Stewart K et al. Safety and efficacy of once daily raltegravir to enhance adherence and efficacy of HAART in vulnerable HIV-infected patients. 52nd ICAAC, 9-12 September 2012, San Francisco. Abstract H-884.
A group of French researchers looking at immunological non-responders despite viral suppression <50 copies/mL reported an association with HIV DNA as a marker of recent cellular infection and ongoing replication and overexpression of the activation marker CD38+, that was higher in patients with reduced CD4 responses on treatment. The natap report linked below report this study in detail.
Ref: Psomas KC et al. Poor CD4+ T-cell restoration linked to residual HIV-1 reverse transcription under antiretroviral therapy. 52nd ICAAC, 9-12 September 2012, San Francisco. Abstract H-1570a.
No comments have been made.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|